Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled

Author(s): Irina Veytsman, Jeanny B. Aragon-Ching, Sandra M. Swain

Journal Name: Current Molecular Pharmacology

Volume 5 , Issue 3 , 2012

Become EABM
Become Reviewer
Call for Editor


The incidence of central nervous system (CNS) metastases secondary to solid tumors is increasing. As more effective systemic therapy is being used in patients with solid tumors, patients with cancer live longer and are ultimately at higher risk for CNS metastases. However, CNS metastases remain challenging to treat because of limited available therapeutic options. This article reviews mechanisms of CNS metastases, the use of bevacizumab and other angiogenesis inhibitors in the treatment of recurrent and front-line CNS metastases, as well as emerging issues of resistance to antiangiogenic therapy.

Keywords: Angiogenesis, angiogenesis inhibitors, bevacizumab, CNS neoplasm

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [382 - 391]
Pages: 10
DOI: 10.2174/1874467211205030007
Price: $65

Article Metrics

PDF: 10